Roche Shelves Drug Acquired from Carmot Therapeutics
Roche has decided to shelve a drug that was part of its acquisition of Carmot Therapeutics. This decision represents a material change in Roche's R&D pipeline and strategy, particularly concerning assets gained through recent acquisitions.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.